Brief: AB Science: Independent Publication Sees Masitinib As Possible Alzheimer's Therapy
08/03/2021 07:21
March 8 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES THAT A NEW INDEPENDENT PUBLICATION
CONFIRMS
THE ROLE OF MASITINIB AS A POTENTIAL THERAPY IN
NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE
Source text: https://bit.ly/3bqeu8r
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease